REG - Genflow Biosciences - Result of GM

Genflow BiosciencesAnnouncement

Mon 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB9654Ua&default-theme=true

RNS Number : 9654U  Genflow Biosciences PLC  02 March 2026

 

2 March 2026

Genflow Biosciences Plc

Results of General Meeting

 

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
a leading European-based biotechnology company focusing on longevity, is
pleased to announce that all resolutions proposed at the General Meeting held
earlier today were duly passed by shareholders. The number of proxy votes for
each resolution submitted prior to the meeting are presented below.

 

Proxy Voting Results

 

 Ordinary Resolutions                                         Votes for    % of votes cast for  Votes Against  % of votes cast against  Votes withheld  Total votes cast
 1. To approve the Director's authority to allot securities.  224,571,419  98.2%                3,787,114      1.7%                     429,987         228,788,520

 Special Resolution                                           Votes for    % of votes cast for  Votes Against  % of votes cast against  Votes withheld  Total votes cast
 2. To disapply statutory pre-emption rights.                 222,245,570  97.1%                5,141,463      2.2%                     1,401,487       228,788,520

 

 Contacts

                       Harbor Access

 Genflow Biosciences
 Dr Eric Leire, CEO    Jonathan Paterson, Investor Relations
 +32-477-495-881       +1 475 477 9401
                       Jonathan.Paterson@Harbor-access.com

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, delivers a proprietary
centenarian variant of the SIRT6 gene. The therapy is currently being
evaluated in the Company's randomised, blinded SLAB (Sarcopenia and Longevity
in Aged Beagles) study in dogs aged over 10 years, which commenced in March
2025. Preliminary interim results demonstrated improved survival versus
control during the dosing period, alongside favourable safety and tolerability
and positive trends across functional endpoints including muscle mass
preservation, frailty reduction and quality of life. Other programs include a
clinical trial that will explore the potential benefits of GF-1002 in treating
MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent
chronic liver disease for which there is no effective treatments. Please
visit www.genflowbio.com (http://www.genflowbio.com/)   and follow the
Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true)
 and X (https://x.com/genflowbio) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMUUUURNKUORAR



            Copyright 2019 Regulatory News Service, all rights reserved